<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03427177</url>
  </required_header>
  <id_info>
    <org_study_id>17-8013</org_study_id>
    <nct_id>NCT03427177</nct_id>
  </id_info>
  <brief_title>Mychoice: Testing an Interactive mHealth Tool</brief_title>
  <official_title>Mychoice: Testing an Interactive mHealth Tool to Enhance Communication and Informed Decision Making About Clinical Trial Participation in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators aim to test a culturally diverse and patient guided mHealth decision tool&#xD;
      called mychoice, which allows patients to explore their concerns and questions related to&#xD;
      clinical trial participation, as well as create a customized and personalized set of&#xD;
      questions to enhance patient-provider communication and increase informed decision making.&#xD;
      This study employs a mixed-methods approach using both qualitative and quantitative data to&#xD;
      evaluate the effectiveness of the mychoice intervention for patients and to explore the&#xD;
      provider and organizational factors that impact implementation. A randomized controlled trial&#xD;
      will be performed with 270 participants in order to determine the acceptability and&#xD;
      feasibility of the intervention, as well as its effects on self-efficacy in discussing&#xD;
      clinical trial participation with providers, leading to enhanced informed decision-making. A&#xD;
      secondary aim of the study is to evaluate the implementation of the intervention in clinical&#xD;
      settings. Implementation evaluation will occur using surveys of medical staff whose patients&#xD;
      are participating in the study. These surveys will assess institutional facilitators and&#xD;
      barriers to study implementation. Investigators will also conduct cognitive de-briefing&#xD;
      interviews after the intervention is completed with key stakeholders at the participating&#xD;
      institutions, which will inform a larger implementation study in the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evidence shows that although clinical trials are aimed at producing new strategies for&#xD;
      reducing cancer morbidity and mortality, participation remains sub-optimal for all&#xD;
      populations, especially those from racial and ethnic groups. Although some interventions have&#xD;
      been found to be effective at enhancing participation, few studies have tested tailored&#xD;
      communication activities using innovative communication techniques (perceptual mapping) with&#xD;
      aims to address barriers and facilitators for patients and facilitate more engaged&#xD;
      discussions with their providers in real world settings.&#xD;
&#xD;
      Participation in clinical trials is a serious and complex decision, and many patients of all&#xD;
      races and backgrounds have limited knowledge and understanding of clinical trials as a&#xD;
      treatment option. Although research has been conducted to explore the barriers to&#xD;
      participation, there has been a call for more intervention research to address these&#xD;
      barriers. A fundamental aspect of patient focused interventions is an exploration of their&#xD;
      personal questions and concerns, without which it is difficult for patients to become&#xD;
      empowered to participate in an informed or shared decision making process. However, there&#xD;
      remains limited empirical research to suggest which messages are most salient to a diverse&#xD;
      range of patients to improve decision making, and how decision tools can be tailored to&#xD;
      enhance patient-provider communication. This research will provide insight into that process&#xD;
      when the decision is participation in clinical trials.&#xD;
&#xD;
      Evidence shows that ethnic and racial minorities are significantly underrepresented in&#xD;
      clinical trials, which is critical to producing new strategies for reducing cancer morbidity&#xD;
      and mortality for all populations. Recognizing the complexity of barriers to participation in&#xD;
      clinical trials, research has focused on potential strategies to enhance participation.&#xD;
      Interventions have shown that provider referrals of minority patients, community outreach,&#xD;
      acknowledging and addressing issues of trust, flexibility in intervention methods, and&#xD;
      population targeted materials are effective. Few studies, however, have tested tailored&#xD;
      communication activities to address barriers and facilitators for patients using innovative&#xD;
      communication techniques in real world settings - meaning ways these activities can be&#xD;
      integrated into the healthcare workflow - or addressed the unique needs of racial and ethnic&#xD;
      minorities.&#xD;
&#xD;
      The mychoice communication tool begins to prepare patients to participate in a personal and&#xD;
      tailored discussion with their provider about clinical trials as a potential treatment&#xD;
      option. The tool is also customized to address the concerns of those least likely to&#xD;
      participate, instead of providing a more general look at clinical trials- a common trait of&#xD;
      other available tools. Previous research has shown that patient education before the first&#xD;
      oncologist visit improves knowledge, attitudes, and preparation for decision making about&#xD;
      clinical trials and integrating these tools into the clinical encounter is critical. In&#xD;
      addition, using innovative communication techniques (perceptual mapping and vector modeling)&#xD;
      to validate and explore notable messages across diverse cancer patients provided new insights&#xD;
      into tailoring messages and personalizing patient/provider communication. Insight gained from&#xD;
      validation of the intervention will improve the decision making process and inform a large&#xD;
      scale integration of mychoice to affect patient perceptions and increase willingness to&#xD;
      participate in clinical trials, especially in minority patients.&#xD;
&#xD;
      In addition, Investigators will assess barriers to implementation when introducing the tool&#xD;
      in diverse cancer centers, each with different protocols and patient populations, to inform a&#xD;
      future proposal. Using the Consolidated Framework for Implementation Science (CFIR), one of&#xD;
      the predominant implementation science research frameworks, we will focus on five domains:&#xD;
      intervention characteristics, outer settings, inner setting, characteristics of individuals&#xD;
      (patients and providers), and process. Implementation science is becoming an important&#xD;
      component of intervention implementation and we aim to use this framework to ensure success.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2018</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">January 21, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perceived Efficacy in Patient-Physician Interactions (PEPPI) Self-Efficacy Scale- Outcome Measure at Baseline, Post-test and One Month Follow-up</measure>
    <time_frame>Baseline and post-test (both occur on same day, day 1), one month follow-up</time_frame>
    <description>10-item scale measuring patient confidence in communicating with their physician. Participants respond to each question on a scale of 1 to 5, with 5 representing &quot;very confident,'' and 1 representing &quot;not at all confident.&quot; The range of possible scores for the full PEPPI scale is 10 to 50 (50 representing highest patient-perceived self-efficacy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CollaboRATE Perceived Shared Decision Making Scale</measure>
    <time_frame>1 month follow-up</time_frame>
    <description>Measure of patient perceptions of physician effort to discuss concerns, 3 items. There is a possible range of 0-9 for each item.&#xD;
Higher scores represent more shared decision making.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shared Decision Making (SDM Q-9) Scale</measure>
    <time_frame>1 month follow-up</time_frame>
    <description>Measure of patient perception of shared decision making with provider (12 items). The instrument's statements are rated on a six-point scale from ''completely disagree'' (0) to ''completely agree'' (5).&#xD;
Higher means indicate higher levels of perceived shared decision making.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ottawa Decisional Conflict</measure>
    <time_frame>Baseline and post-test (both occur on same day, day 1), one month follow-up</time_frame>
    <description>13 item measure to determine patient clarity on the risks and benefits of clinical trials, support from friends and family, and patient decision regarding cancer treatment. Items are given a score value of: 0= 'strongly agree'; 2= 'neither agree nor disagree'; 3= 'disagree'; 4= 'strongly disagree' TOTAL SCORE 16 items [items 1-16 are inclusive] are: a) summed; b) divided by 16; and c) multiplied by 25. Scores range from 0 [no decisional conflict] to 100 [extremely high decisional conflict]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preparation for Decision Making (PrepDM) Scale</measure>
    <time_frame>Post test (day 1)</time_frame>
    <description>Measures preparedness of patient to make a decision (10 items) on a 1 &quot;not at all&quot; to 5 &quot;a great deal&quot; scale.&#xD;
Higher means indicated higher perceived level of preparation for decision making.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">257</enrollment>
  <condition>Conflict</condition>
  <condition>Decisional Conflict</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the treatment arm of the study will be given the mychoice tool.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>mychoice</intervention_name>
    <description>The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or over&#xD;
&#xD;
          -  Active diagnosis of invasive cancer (any diagnoses), pre or post&#xD;
             chemo/radiation/surgery&#xD;
&#xD;
          -  Able to speak and read English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participated in a therapeutic trial in the past&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Fleisher, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarah Bass, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Baquet CR, Henderson K, Commiskey P, Morrow JN. Clinical trials: the art of enrollment. Semin Oncol Nurs. 2008 Nov;24(4):262-9. doi: 10.1016/j.soncn.2008.08.006.</citation>
    <PMID>19000600</PMID>
  </reference>
  <reference>
    <citation>Comis R, Crowley J. Baseline study of patient accrual onto publically sponsored U.S. cancer clinical trials: an analysis conducted for the global access project of the national patient advocate foundation, 2006.</citation>
  </reference>
  <reference>
    <citation>Michaels, M.S., S; ENACCT and Community-Campus Partnerships for Health, Communities as Partners in Cancer Clinical Trials: Changing Research, Practice and Policy. 2008: Silver Springs, MD.</citation>
  </reference>
  <reference>
    <citation>Weinberg, A.D. Eliminating Disparities in Clinical Trials. cited 2009 June 4th, 2009; Version 2: Available from: http://www.bcm.edu/edict/home.html.</citation>
  </reference>
  <reference>
    <citation>Colon-Otero G, Smallridge RC, Solberg LA Jr, Keith TD, Woodward TA, Willis FB, Dunn AN. Disparities in participation in cancer clinical trials in the United States : a symptom of a healthcare system in crisis. Cancer. 2008 Feb 1;112(3):447-54.</citation>
    <PMID>18085590</PMID>
  </reference>
  <reference>
    <citation>Gadegbeku CA, Stillman PK, Huffman MD, Jackson JS, Kusek JW, Jamerson KA. Factors associated with enrollment of African Americans into a clinical trial: results from the African American study of kidney disease and hypertension. Contemp Clin Trials. 2008 Nov;29(6):837-42. doi: 10.1016/j.cct.2008.06.001. Epub 2008 Jun 27.</citation>
    <PMID>18639652</PMID>
  </reference>
  <reference>
    <citation>Katz RV, Wang MQ, Green BL, Kressin NR, Claudio C, Russell SL, Sommervil C. Participation in biomedical research studies and cancer screenings: perceptions of risks to minorities compared with whites. Cancer Control. 2008 Oct;15(4):344-51.</citation>
    <PMID>18813202</PMID>
  </reference>
  <reference>
    <citation>Shavers VL, Lynch CF, Burmeister LF. Factors that influence African-Americans' willingness to participate in medical research studies. Cancer. 2001 Jan 1;91(1 Suppl):233-6. Erratum in: Cancer 2001 Mar 15;91(6):1187.</citation>
    <PMID>11148585</PMID>
  </reference>
  <reference>
    <citation>Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K, Ellis P, Wright JR. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol. 2006 Feb;7(2):141-8. Review.</citation>
    <PMID>16455478</PMID>
  </reference>
  <reference>
    <citation>Todd AM, Laird BJ, Boyle D, Boyd AC, Colvin LA, Fallon MT. A systematic review examining the literature on attitudes of patients with advanced cancer toward research. J Pain Symptom Manage. 2009 Jun;37(6):1078-85. doi: 10.1016/j.jpainsymman.2008.07.009. Epub 2009 May 5. Review.</citation>
    <PMID>19419837</PMID>
  </reference>
  <reference>
    <citation>Evelyn B, Toigo T, Banks D, Pohl D, Gray K, Robins B, Ernat J. Participation of racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular entities approved 1995-1999. J Natl Med Assoc. 2001 Dec;93(12 Suppl):18S-24S. Review.</citation>
    <PMID>11798060</PMID>
  </reference>
  <reference>
    <citation>Stewart JH, Bertoni AG, Staten JL, Levine EA, Gross CP. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol. 2007 Dec;14(12):3328-34. Epub 2007 Aug 8.</citation>
    <PMID>17682824</PMID>
  </reference>
  <reference>
    <citation>Rivera-Goba MV, Dominguez DC, Stoll P, Grady C, Ramos C, Mican JM. Exploring decision-making of HIV-infected Hispanics and African Americans participating in clinical trials. J Assoc Nurses AIDS Care. 2011 Jul-Aug;22(4):295-306. doi: 10.1016/j.jana.2010.10.007. Epub 2011 Jan 21.</citation>
    <PMID>21256054</PMID>
  </reference>
  <reference>
    <citation>Symonds RP, Lord K, Mitchell AJ, Raghavan D. Recruitment of ethnic minorities into cancer clinical trials: experience from the front lines. Br J Cancer. 2012 Sep 25;107(7):1017-21. doi: 10.1038/bjc.2012.240. Epub 2012 May 31. Review.</citation>
    <PMID>23011540</PMID>
  </reference>
  <reference>
    <citation>Schmotzer GL. Barriers and facilitators to participation of minorities in clinical trials. Ethn Dis. 2012 Spring;22(2):226-30. Review.</citation>
    <PMID>22764647</PMID>
  </reference>
  <reference>
    <citation>Advani AS, Atkeson B, Brown CL, Peterson BL, Fish L, Johnson JL, Gockerman JP, Gautier M. Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study. Cancer. 2003 Mar 15;97(6):1499-506.</citation>
    <PMID>12627515</PMID>
  </reference>
  <reference>
    <citation>Goldberg D. The case for Eliminating Disparities in Clinical Trials. J Cancer Educ. 2009;24(2 Suppl):S34-8. doi: 10.1080/08858190903400484.</citation>
    <PMID>20024824</PMID>
  </reference>
  <reference>
    <citation>Gross CP. Racial disparities in clinical trial enrolment. Lancet. 2008 Nov 15;372(9651):1713-4. doi: 10.1016/S0140-6736(08)61714-6.</citation>
    <PMID>19013309</PMID>
  </reference>
  <reference>
    <citation>Newman LA, Roff NK, Weinberg AD. Cancer clinical trials accrual: missed opportunities to address disparities and missed opportunities to improve outcomes for all. Ann Surg Oncol. 2008 Jul;15(7):1818-9. doi: 10.1245/s10434-008-9869-2. Epub 2008 Apr 19.</citation>
    <PMID>18425554</PMID>
  </reference>
  <reference>
    <citation>Ford JG, Howerton MW, Lai GY, Gary TL, Bolen S, Gibbons MC, Tilburt J, Baffi C, Tanpitukpongse TP, Wilson RF, Powe NR, Bass EB. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008 Jan 15;112(2):228-42. Review.</citation>
    <PMID>18008363</PMID>
  </reference>
  <reference>
    <citation>Gul RB, Ali PA. Clinical trials: the challenge of recruitment and retention of participants. J Clin Nurs. 2010 Jan;19(1-2):227-33. doi: 10.1111/j.1365-2702.2009.03041.x.</citation>
    <PMID>20500260</PMID>
  </reference>
  <reference>
    <citation>Markman M, Petersen J, Montgomery R. An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials. J Cancer Res Clin Oncol. 2008 Jan;134(1):115-8. Epub 2007 Jun 28.</citation>
    <PMID>17598129</PMID>
  </reference>
  <reference>
    <citation>Adderley-Kelly B, Green PM. Strategies for successful conduct of research with low-income African American populations. Nurs Outlook. 2005 May-Jun;53(3):147-52. Review.</citation>
    <PMID>15988452</PMID>
  </reference>
  <reference>
    <citation>Knobf MT, Juarez G, Lee SY, Sun V, Sun Y, Haozous E. Challenges and strategies in recruitment of ethnically diverse populations for cancer nursing research. Oncol Nurs Forum. 2007 Nov;34(6):1187-94. Review.</citation>
    <PMID>18024345</PMID>
  </reference>
  <reference>
    <citation>Lai GY, Gary TL, Tilburt J, Bolen S, Baffi C, Wilson RF, Howerton MW, Gibbons MC, Tanpitukpongse TP, Powe NR, Bass EB, Ford JG. Effectiveness of strategies to recruit underrepresented populations into cancer clinical trials. Clin Trials. 2006;3(2):133-41. Review.</citation>
    <PMID>16773955</PMID>
  </reference>
  <reference>
    <citation>Davis SW, Fleisher L, Ter Maat J, Muha C, Laepke K. Treatment and clinical trials decisionmaking: the impact of the Cancer Information Service. Part 5. J Health Commun. 1998;3 Suppl:71-85.</citation>
    <PMID>10977271</PMID>
  </reference>
  <reference>
    <citation>Meropol NJ, Wong YN, Albrecht T, Manne S, Miller SM, Flamm AL, Benson AB 3rd, Buzaglo J, Collins M, Egleston B, Fleisher L, Katz M, Kinzy TG, Liu TM, Margevicius S, Miller DM, Poole D, Roach N, Ross E, Schluchter MD. Randomized Trial of a Web-Based Intervention to Address Barriers to Clinical Trials. J Clin Oncol. 2016 Feb 10;34(5):469-78. doi: 10.1200/JCO.2015.63.2257. Epub 2015 Dec 23.</citation>
    <PMID>26700123</PMID>
  </reference>
  <reference>
    <citation>Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009 Aug 7;4:50. doi: 10.1186/1748-5908-4-50.</citation>
    <PMID>19664226</PMID>
  </reference>
  <reference>
    <citation>Denicoff AM, McCaskill-Stevens W, Grubbs SS, Bruinooge SS, Comis RL, Devine P, Dilts DM, Duff ME, Ford JG, Joffe S, Schapira L, Weinfurt KP, Michaels M, Raghavan D, Richmond ES, Zon R, Albrecht TL, Bookman MA, Dowlati A, Enos RA, Fouad MN, Good M, Hicks WJ, Loehrer PJ Sr, Lyss AP, Wolff SN, Wujcik DM, Meropol NJ. The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. J Oncol Pract. 2013 Nov;9(6):267-76. doi: 10.1200/JOP.2013.001119. Epub 2013 Oct 15.</citation>
    <PMID>24130252</PMID>
  </reference>
  <reference>
    <citation>Maly RC, Frank JC, Marshall GN, DiMatteo MR, Reuben DB. Perceived efficacy in patient-physician interactions (PEPPI): validation of an instrument in older persons. J Am Geriatr Soc. 1998 Jul;46(7):889-94.</citation>
    <PMID>9670878</PMID>
  </reference>
  <reference>
    <citation>Bennett C, Graham ID, Kristjansson E, Kearing SA, Clay KF, O'Connor AM. Validation of a preparation for decision making scale. Patient Educ Couns. 2010 Jan;78(1):130-3. doi: 10.1016/j.pec.2009.05.012. Epub 2009 Jun 26.</citation>
    <PMID>19560303</PMID>
  </reference>
  <reference>
    <citation>O'Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995 Jan-Mar;15(1):25-30.</citation>
    <PMID>7898294</PMID>
  </reference>
  <reference>
    <citation>Kriston L, Scholl I, Hölzel L, Simon D, Loh A, Härter M. The 9-item Shared Decision Making Questionnaire (SDM-Q-9). Development and psychometric properties in a primary care sample. Patient Educ Couns. 2010 Jul;80(1):94-9. doi: 10.1016/j.pec.2009.09.034. Epub 2009 Oct 30.</citation>
    <PMID>19879711</PMID>
  </reference>
  <reference>
    <citation>Barr PJ, Thompson R, Walsh T, Grande SW, Ozanne EM, Elwyn G. Correction: the psychometric properties of CollaboRATE: a fast and frugal patient-reported measure of the shared decision-making process. J Med Internet Res. 2015 Feb 6;17(2):e32. doi: 10.2196/jmir.4272.</citation>
    <PMID>25667387</PMID>
  </reference>
  <reference>
    <citation>National Institutes for Health (NIH). NIH Demographics form Version 2.0.</citation>
  </reference>
  <reference>
    <citation>NCI's Health and Information National Trend Study. Computer Facility. PIES Study (Diefenbach et al)</citation>
  </reference>
  <reference>
    <citation>Morris NS, MacLean CD, Chew LD, Littenberg B. The Single Item Literacy Screener: evaluation of a brief instrument to identify limited reading ability. BMC Fam Pract. 2006 Mar 24;7:21.</citation>
    <PMID>16563164</PMID>
  </reference>
  <reference>
    <citation>Hoerger M, Chapman BP, Mohile SG, Duberstein PR. Development and psychometric evaluation of the Decisional Engagement Scale (DES-10): A patient-reported psychosocial survey for quality cancer care. Psychol Assess. 2016 Sep;28(9):1087-100. doi: 10.1037/pas0000294.</citation>
    <PMID>27537003</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>February 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <results_first_submitted>November 17, 2020</results_first_submitted>
  <results_first_submitted_qc>December 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 12, 2021</results_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03427177/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Participants randomized to the treatment arm of the study will be given the mychoice tool.&#xD;
mychoice: The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The number of participants in the Baseline Analysis Population only includes participants who completed the baseline survey in it's entirety. 257 participants were consented and joined the study; however, they did not complete any study tasks and no data was completed at baseline. 250 participants completed baseline.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Participants randomized to the treatment arm of the study will be given the mychoice tool.&#xD;
mychoice: The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="122"/>
            <count group_id="B2" value="128"/>
            <count group_id="B3" value="250"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Perceived Efficacy in Patient-Physician Interactions (PEPPI) Self-Efficacy Scale- Outcome Measure at Baseline, Post-test and One Month Follow-up</title>
        <description>10-item scale measuring patient confidence in communicating with their physician. Participants respond to each question on a scale of 1 to 5, with 5 representing &quot;very confident,'' and 1 representing &quot;not at all confident.&quot; The range of possible scores for the full PEPPI scale is 10 to 50 (50 representing highest patient-perceived self-efficacy).</description>
        <time_frame>Baseline and post-test (both occur on same day, day 1), one month follow-up</time_frame>
        <population>There was participant drop off between baseline, post-test, and follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants randomized to the treatment arm of the study will be given the mychoice tool.&#xD;
mychoice: The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived Efficacy in Patient-Physician Interactions (PEPPI) Self-Efficacy Scale- Outcome Measure at Baseline, Post-test and One Month Follow-up</title>
          <description>10-item scale measuring patient confidence in communicating with their physician. Participants respond to each question on a scale of 1 to 5, with 5 representing &quot;very confident,'' and 1 representing &quot;not at all confident.&quot; The range of possible scores for the full PEPPI scale is 10 to 50 (50 representing highest patient-perceived self-efficacy).</description>
          <population>There was participant drop off between baseline, post-test, and follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" spread="5.8"/>
                    <measurement group_id="O2" value="44.0" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-test</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="6.5"/>
                    <measurement group_id="O2" value="44.4" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8" spread="6.0"/>
                    <measurement group_id="O2" value="44.2" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CollaboRATE Perceived Shared Decision Making Scale</title>
        <description>Measure of patient perceptions of physician effort to discuss concerns, 3 items. There is a possible range of 0-9 for each item.&#xD;
Higher scores represent more shared decision making.</description>
        <time_frame>1 month follow-up</time_frame>
        <population>Participants were only asked these questions if their doctor talked to them about participating in a clinical trial prior to completing follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants randomized to the treatment arm of the study will be given the mychoice tool.&#xD;
mychoice: The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).</description>
          </group>
        </group_list>
        <measure>
          <title>CollaboRATE Perceived Shared Decision Making Scale</title>
          <description>Measure of patient perceptions of physician effort to discuss concerns, 3 items. There is a possible range of 0-9 for each item.&#xD;
Higher scores represent more shared decision making.</description>
          <population>Participants were only asked these questions if their doctor talked to them about participating in a clinical trial prior to completing follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>How much effort was made to help you understand clinical trials?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" spread="1.185"/>
                    <measurement group_id="O2" value="3.74" spread="1.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How much effort was made to listen to the things that matter most to you about clinical trials?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" spread="1.300"/>
                    <measurement group_id="O2" value="3.71" spread="1.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How much effort was made to include what matters most to you in choosing what to do next?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" spread="1.185"/>
                    <measurement group_id="O2" value="3.69" spread="1.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Shared Decision Making (SDM Q-9) Scale</title>
        <description>Measure of patient perception of shared decision making with provider (12 items). The instrument's statements are rated on a six-point scale from ''completely disagree'' (0) to ''completely agree'' (5).&#xD;
Higher means indicate higher levels of perceived shared decision making.</description>
        <time_frame>1 month follow-up</time_frame>
        <population>Only participants who were offered a clinical trial were asked these questions.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants randomized to the treatment arm of the study will be given the mychoice tool.&#xD;
mychoice: The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).</description>
          </group>
        </group_list>
        <measure>
          <title>Shared Decision Making (SDM Q-9) Scale</title>
          <description>Measure of patient perception of shared decision making with provider (12 items). The instrument's statements are rated on a six-point scale from ''completely disagree'' (0) to ''completely agree'' (5).&#xD;
Higher means indicate higher levels of perceived shared decision making.</description>
          <population>Only participants who were offered a clinical trial were asked these questions.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>My doctor made it clear that a decision needs to be made.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.19" spread="1.642"/>
                    <measurement group_id="O2" value="4.09" spread="1.652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>My doctor wanted to know exactly how I want to be involved in making a decision.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.29" spread="1.657"/>
                    <measurement group_id="O2" value="4.23" spread="1.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>My doctor toldme that there are different options for treating my medical condition.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" spread="1.237"/>
                    <measurement group_id="O2" value="4.67" spread="1.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>My doctor precisely explained the advantages and disadvantages of clinical trials.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.13" spread="1.755"/>
                    <measurement group_id="O2" value="4.20" spread="1.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>My doctor helped me understand all the information for clinical trials.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.90" spread="1.578"/>
                    <measurement group_id="O2" value="4.29" spread="1.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>My doctor asked me which treatment option I prefer.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="1.798"/>
                    <measurement group_id="O2" value="4.49" spread="1.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>My doctor and I thoroughly weighed the different treatment options.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.19" spread="1.857"/>
                    <measurement group_id="O2" value="4.69" spread="1.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>My doctor and I selected a treatment option together.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.66" spread="1.619"/>
                    <measurement group_id="O2" value="4.54" spread="1.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>My doctor and I reached an agreement on how to proceed.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" spread="1.52"/>
                    <measurement group_id="O2" value="4.60" spread=".479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ottawa Decisional Conflict</title>
        <description>13 item measure to determine patient clarity on the risks and benefits of clinical trials, support from friends and family, and patient decision regarding cancer treatment. Items are given a score value of: 0= 'strongly agree'; 2= 'neither agree nor disagree'; 3= 'disagree'; 4= 'strongly disagree' TOTAL SCORE 16 items [items 1-16 are inclusive] are: a) summed; b) divided by 16; and c) multiplied by 25. Scores range from 0 [no decisional conflict] to 100 [extremely high decisional conflict]</description>
        <time_frame>Baseline and post-test (both occur on same day, day 1), one month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants randomized to the treatment arm of the study will be given the mychoice tool.&#xD;
mychoice: The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).</description>
          </group>
        </group_list>
        <measure>
          <title>Ottawa Decisional Conflict</title>
          <description>13 item measure to determine patient clarity on the risks and benefits of clinical trials, support from friends and family, and patient decision regarding cancer treatment. Items are given a score value of: 0= 'strongly agree'; 2= 'neither agree nor disagree'; 3= 'disagree'; 4= 'strongly disagree' TOTAL SCORE 16 items [items 1-16 are inclusive] are: a) summed; b) divided by 16; and c) multiplied by 25. Scores range from 0 [no decisional conflict] to 100 [extremely high decisional conflict]</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" spread="19.8"/>
                    <measurement group_id="O2" value="31.6" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="147"/>
                    <measurement group_id="O2" value="26.2" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" spread="18.3"/>
                    <measurement group_id="O2" value="28.7" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preparation for Decision Making (PrepDM) Scale</title>
        <description>Measures preparedness of patient to make a decision (10 items) on a 1 &quot;not at all&quot; to 5 &quot;a great deal&quot; scale.&#xD;
Higher means indicated higher perceived level of preparation for decision making.</description>
        <time_frame>Post test (day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants randomized to the treatment arm of the study will be given the mychoice tool.&#xD;
mychoice: The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).</description>
          </group>
        </group_list>
        <measure>
          <title>Preparation for Decision Making (PrepDM) Scale</title>
          <description>Measures preparedness of patient to make a decision (10 items) on a 1 &quot;not at all&quot; to 5 &quot;a great deal&quot; scale.&#xD;
Higher means indicated higher perceived level of preparation for decision making.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>How much did the edu... Help you recognize that a decision needs to be made about clinical trials?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.1"/>
                    <measurement group_id="O2" value="3.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prepare you to make a better decision about clinical trials?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread=".9"/>
                    <measurement group_id="O2" value="3.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Help you think about the pros and cons of treatment options?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.0"/>
                    <measurement group_id="O2" value="3.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Help you think about which pros and cons are most important?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.0"/>
                    <measurement group_id="O2" value="3.8" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Help you know that the decision depends on what matters most to you?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread=".9"/>
                    <measurement group_id="O2" value="4.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Help you organize your own thoughts about the decision?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="1.0"/>
                    <measurement group_id="O2" value="3.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Help you think about how involved you want to be in this decision?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.0"/>
                    <measurement group_id="O2" value="4.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Help you identify questions you want to ask your doctor?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread=".9"/>
                    <measurement group_id="O2" value="4.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prepare you to talk to your doctor about what matters most to you?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread=".9"/>
                    <measurement group_id="O2" value="4.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prepare you for a follow-up visit with your doctor?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.0"/>
                    <measurement group_id="O2" value="3.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected between baseline and one-month follow-up.</time_frame>
      <desc>This was a minimal risk study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Participants randomized to the treatment arm of the study will be given the mychoice tool.&#xD;
mychoice: The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Linda Fleisher</name_or_title>
      <organization>Fox Chase Cancer Center</organization>
      <phone>215-214-3757</phone>
      <email>Linda.Fleisher@fccc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

